You are here

FDA Gives “Thumbs Down” to Oral Testosterone Therapy

Agency questions dosing algorithm

Lipocine, Inc., has received a complete response letter (CRL) from the FDA regarding its new drug application for LPCN 1021, an oral testosterone product candidate for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).

A CRL is a communication from the FDA that informs companies that an application cannot be approved in its present form. The CRL identified deficiencies related to the dosing algorithm for the LPCN 1021 label. Specifically, the proposed titration scheme for clinical practice was significantly different from the titration scheme used in the phase 3 trial, leading to discordance in titration decisions between the phase 3 trial and real-world clinical practice.

Lipocine plans to request a meeting with the FDA to agree on a path forward to achieve approval of LPCN 1021.

LPCN 1021 is a twice-a-day oral testosterone replacement therapy product candidate that is designed to help restore normal testosterone levels in hypogonadal men.

The current testosterone market primarily uses short-acting injectable products as well as topical products that carry an FDA boxed warning related to inadvertent transfer of testosterone to others. According to the IMS Health database, an average of half a million prescriptions a month have been dispensed in 2016 for testosterone replacement therapy.

Source: Lipocine; June 29, 2016.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time